Yu ZH - Search Results

1

Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer.

Bao Y, Peng F, Zhou QC, Yu ZH, Li JC, Cheng ZB, Chen L, Hu X, Chen YY, Wang J, Wang Y, Ma HL, Xu ZM, Lu RB, Deng XW, Chen M. Bao Y, et al. Among authors: yu zh. Radiother Oncol. 2015 Feb;114(2):161-6. doi: 10.1016/j.radonc.2014.11.039. Epub 2014 Dec 9. Radiother Oncol. 2015. PMID: 25497558 Clinical Trial.

2

Efficacy and tolerability of docetaxel and cisplatin plus S-1 for advanced gastric cancer.

Luo H, Yu Z, Gao H, Guan C, Xu M. Luo H, et al. J BUON. 2013 Jan-Mar;18(1):154-61. J BUON. 2013. PMID: 23613401 Free article.

3

A new version of targeted minicircle producer system for EBV-positive human nasopharyngeal carcinoma.

Zuo Y, Liao S, Xu Z, Xie J, Huang W, Yu Z. Zuo Y, et al. Oncol Rep. 2014 Dec;32(6):2564-70. doi: 10.3892/or.2014.3486. Epub 2014 Sep 17. Oncol Rep. 2014. PMID: 25230680

4

Metformin inhibits the growth of nasopharyngeal carcinoma cells and sensitizes the cells to radiation via inhibition of the DNA damage repair pathway.

Li H, Chen X, Yu Y, Wang Z, Zuo Y, Li S, Yang D, Hu S, Xiang M, Xu Z, Yu Z. Li H, et al. Oncol Rep. 2014 Dec;32(6):2596-604. doi: 10.3892/or.2014.3485. Epub 2014 Sep 17. Oncol Rep. 2014. PMID: 25333332

5

Antisense oligonucleotides targeting human telomerase mRNA increases the radiosensitivity of nasopharyngeal carcinoma cells.

Yu C, Yu Y, Xu Z, Li H, Yang D, Xiang M, Zuo Y, Li S, Chen Z, Yu Z. Yu C, et al. Mol Med Rep. 2015 Apr;11(4):2825-30. doi: 10.3892/mmr.2014.3105. Epub 2014 Dec 17. Mol Med Rep. 2015. PMID: 25523013

6

Overexpression of the regulator of G-protein signaling 5 reduces the survival rate and enhances the radiation response of human lung cancer cells.

Xu Z, Zuo Y, Wang J, Yu Z, Peng F, Chen Y, Dong Y, Hu X, Zhou Q, Ma H, Bao Y, Chen M. Xu Z, et al. Oncol Rep. 2015 Jun;33(6):2899-907. doi: 10.3892/or.2015.3917. Epub 2015 Apr 20. Oncol Rep. 2015. PMID: 25891540

7

Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.

Zhang W, Zhou H, Yu Y, Li J, Li H, Jiang D, Chen Z, Yang D, Xu Z, Yu Z. Zhang W, et al. Onco Targets Ther. 2016 Jun 2;9:3359-68. doi: 10.2147/OTT.S100936. eCollection 2016. Onco Targets Ther. 2016. PMID: 27330316 Free PMC article.

8

Niclosamide enhances the antitumor effects of radiation by inhibiting the hypoxia-inducible factor-1α/vascular endothelial growth factor signaling pathway in human lung cancer cells.

Xiang M, Chen Z, Yang D, Li H, Zuo Y, Li J, Zhang W, Zhou H, Jiang D, Xu Z, Yu Z. Xiang M, et al. Oncol Lett. 2017 Aug;14(2):1933-1938. doi: 10.3892/ol.2017.6372. Epub 2017 Jun 12. Oncol Lett. 2017. PMID: 28781637 Free PMC article.

9

Matrine suppresses the migration and invasion of NSCLC cells by inhibiting PAX2-induced epithelial-mesenchymal transition.

Yang J, He D, Peng Y, Zhong H, Deng Y, Yu Z, Guan C, Zuo Y, Xu Z. Yang J, et al. Onco Targets Ther. 2017 Oct 27;10:5209-5217. doi: 10.2147/OTT.S149609. eCollection 2017. Onco Targets Ther. 2017. Retraction in: Onco Targets Ther. 2023 Mar 29;16:213-214. doi: 10.2147/OTT.S414610 PMID: 29138573 Free PMC article. Retracted.

10

Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc.

Zuo Y, Yang D, Yu Y, Xiang M, Li H, Yang J, Li J, Jiang D, Zhou H, Xu Z, Yu Z. Zuo Y, et al. Mol Med Rep. 2018 Mar;17(3):3497-3502. doi: 10.3892/mmr.2017.8301. Epub 2017 Dec 18. Mol Med Rep. 2018. PMID: 29257330 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

454 results

Search Page

Filters